Synta Pharmaceuticals Inc.  (SNTA) Trade Now »     Rate SNTA  -  Discuss SNTA  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

SNTA Analysis & Videos »


SNTA: Bull or Bear?

Top 10 Most Profitable Micro Cap Stocks: SNTA, BDSI, IMMU, LUNA, NCT, DX, ADC, TECJQ, CKX, PTX (Aug 04, 2010) SNTA

62%

+23.22% in 670 days http://suprastock.blogspot.com/2010/08/top-10-most-profitable... http://suprastock.blogspot.com/ Synta Pharmaceuticals Corp. (NASDAQ:SNTA) is the 1st most profitable stock in this segment of the market. Its net profit margin was 64.89% for the last 12 months. Its operating profit margin was 65.03% for the same period. Continue reading »

By  Marian Filo   (-24.55%  risk: aggressive)  08/05/10

18 comments

Synta Pharmaceuticals Corp. (SNTA) is HOT, 100% , 1 Year SNTA

N/A

+3.51% in 62 days (closed on 03/16/10) Insiders are buying High increase in Revenue and EPS SNTA outperform S&P500 last 3m Make 100000$ a year online is easy: http://www.money-top10.com/ 1300% gain last year:    http://www.stockpicksexpert.com/ Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. It has a global partnership with Roche for developing novel CRACM inhibitors, an... Continue reading »

By  stockexpert   (-5.25%  risk: conservative)  01/13/10

4 comments

Synta Pharma Proceeds with Clinical Trial SNTA

73%

-99.00% in 1176 days Visit the BioMedReports.com research section to view or download the PDF for Synta Pharma (SNTA) along with other free PDF reports and presentations: http://biomedreports.com/research.html Synta Pharma: Price: $1.94; Market Cap (MM): $65.8 Market Perform; Simos Simeonidis, Ph.D. - Senior Biotech Analyst, Rodman & Renshaw Synta moves forward with investment in Phase I/II trial before GSK decision  <> <> The News:Synta announced this morning that they have dosed the first patient in an open-label, dose-finding, safety and efficacy Phase I/II study with twice-... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  03/17/09

3 comments

Research Note on Synta Pharma (SNTA) SNTA

73%

-0.50% in 4 days (closed on 03/17/09)   <> Synta Pharma (SNTA): Price: $1.97; Market Cap (MM): $66.8 Market Perform; Simos Simeonidis, Ph.D. Senior Biotechnology Analyst <> http://biomedreports.com/research.html Synta cuts 42% of workforce; waiting for strategic alternatives guidance The News: Synta announced today a 42% reduction in its workforce, laying off 90 employees, in an effort to preserve its cash balance, following the failure of the Phase III melanoma trial with Elescomol, the company’s only late stage program. Our view: This was an anticipated and ... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  03/13/09

12 comments

Healthcare Catalyst Stocks for 1H09 SNTA

73%

-72.40% in 65 days (closed on 03/13/09) Healthcare Catalyst Stocks for 1H09 <> Below are four companies I have not written about recently with expected catalysts in the first half of 2009 in the form of FDA decisions or clinical trial results. FDA Calendar of New Product Decisions Last Fall, Discovery Labs (DSCO) received word from the FDA that its complete response for Surfaxin was accepted, but the six-month Class II review designation means that the decision date is pushed out to mid-April. DSCO presents a model trade on a pending FDA decision at this time since it will likely enjoy a run-up in ... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  01/07/09

3 comments

Healthcare Catalyst Stocks for 1H09 SNTA

73%

+0.00% in 0 minute (closed on 01/07/09) Healthcare Catalyst Stocks for 1H09 <> Below are four companies I have not written about recently with expected catalysts in the first half of 2009 in the form of FDA decisions or clinical trial results. FDA Calendar of New Product Decisions Last Fall, Discovery Labs (DSCO) received word from the FDA that its complete response for Surfaxin was accepted, but the six-month Class II review designation means that the decision date is pushed out to mid-April. DSCO presents a model trade on a pending FDA decision at this time since it will likely enjoy a run-up in ... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  01/07/09

1 comment

Healthcare Catalyst Stocks for 1H09 SNTA

73%

+0.00% in 0 minute (closed on 01/07/09) Healthcare Catalyst Stocks for 1H09 <> Below are four companies I have not written about recently with expected catalysts in the first half of 2009 in the form of FDA decisions or clinical trial results. FDA Calendar of New Product Decisions Last Fall, Discovery Labs (DSCO) received word from the FDA that its complete response for Surfaxin was accepted, but the six-month Class II review designation means that the decision date is pushed out to mid-April. DSCO presents a model trade on a pending FDA decision at this time since it will likely enjoy a run-up in ... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  01/07/09

4 comments

Will Synta Break A 30-Year Old Record? (Part II) SNTA

-39.70% in 1496 days For the first part of this article click here. <>Synta (SNTA) launched a phase I trial in 2004 for the evaluation of elesclomol in combination with paclitaxel in advanced solid tumors.<!--more--> The trial enrolled 35 highly-pretreated patients, who received paclitaxel in combination with escalating doses of elesclomol. There were two partial responses (5.7%), one patient with kaposi’s sarcoma and another patient with ovarian cancer in addition to 15 patients who achieved stable disease. Because this was a combination trial, there was no way of knowing whether elesclomol had a synergistic ef... Continue reading »

By  Ohad Hammer   (-13.87%  risk: moderate)  04/30/08

Comment

People Bullish on SNTA

Marian Filo Principal 62% about 1 year ago	schadenfreud Analyst N/A over 2 years ago	Ohad Hammer Tracked Blogger N/A over 4 years ago
masterwuh Analyst  8 % over 4 years ago	curry Analyst 12% over 4 years ago

People Bearish on SNTA

Mike Havrilla Principal 73% over 3 years ago

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.